Report Detail

Request for Sample of this report

Other Global Castration-resistant Prostate Cancer Drugs Market 2025 by Company, Regions, Type and Application, Forecast to 2031

  • RnM4626439
    • |
  • 10 September, 2025
    • |
  • Global
    • |
  • 114 Pages
    • |
  • GIR
    • |
  • Other

According to our (Global Info Research) latest study, the global Castration-resistant Prostate Cancer Drugs market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Castration-resistant Prostate Cancer Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Castration-resistant Prostate Cancer Drugs market size and forecasts, in consumption value ($ Million), 2020-2031
Global Castration-resistant Prostate Cancer Drugs market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Castration-resistant Prostate Cancer Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Castration-resistant Prostate Cancer Drugs market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Castration-resistant Prostate Cancer Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Castration-resistant Prostate Cancer Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Astellas, Janssen, AstraZeneca, Bayer, Hengrui, CTTQ, Sanofi, Hansoh, Clovis Oncology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Castration-resistant Prostate Cancer Drugs market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Oral
Intravenous Injection
Others
Market segment by Application
Hospital
Specialty Clinic
Others
Market segment by players, this report covers
Pfizer
Astellas
Janssen
AstraZeneca
Bayer
Hengrui
CTTQ
Sanofi
Hansoh
Clovis Oncology
Zhendong Pharmaceutical
Merck
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Castration-resistant Prostate Cancer Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Castration-resistant Prostate Cancer Drugs, with revenue, gross margin, and global market share of Castration-resistant Prostate Cancer Drugs from 2020 to 2025.
Chapter 3, the Castration-resistant Prostate Cancer Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Castration-resistant Prostate Cancer Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Castration-resistant Prostate Cancer Drugs.
Chapter 13, to describe Castration-resistant Prostate Cancer Drugs research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Castration-resistant Prostate Cancer Drugs by Type
    • 1.3.1 Overview: Global Castration-resistant Prostate Cancer Drugs Market Size by Type: 2020 Versus 2024 Versus 2031
    • 1.3.2 Global Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Type in 2024
    • 1.3.3 Oral
    • 1.3.4 Intravenous Injection
    • 1.3.5 Others
  • 1.4 Global Castration-resistant Prostate Cancer Drugs Market by Application
    • 1.4.1 Overview: Global Castration-resistant Prostate Cancer Drugs Market Size by Application: 2020 Versus 2024 Versus 2031
    • 1.4.2 Hospital
    • 1.4.3 Specialty Clinic
    • 1.4.4 Others
  • 1.5 Global Castration-resistant Prostate Cancer Drugs Market Size & Forecast
  • 1.6 Global Castration-resistant Prostate Cancer Drugs Market Size and Forecast by Region
    • 1.6.1 Global Castration-resistant Prostate Cancer Drugs Market Size by Region: 2020 VS 2024 VS 2031
    • 1.6.2 Global Castration-resistant Prostate Cancer Drugs Market Size by Region, (2020-2031)
    • 1.6.3 North America Castration-resistant Prostate Cancer Drugs Market Size and Prospect (2020-2031)
    • 1.6.4 Europe Castration-resistant Prostate Cancer Drugs Market Size and Prospect (2020-2031)
    • 1.6.5 Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size and Prospect (2020-2031)
    • 1.6.6 South America Castration-resistant Prostate Cancer Drugs Market Size and Prospect (2020-2031)
    • 1.6.7 Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size and Prospect (2020-2031)

2 Company Profiles

  • 2.1 Pfizer
    • 2.1.1 Pfizer Details
    • 2.1.2 Pfizer Major Business
    • 2.1.3 Pfizer Castration-resistant Prostate Cancer Drugs Product and Solutions
    • 2.1.4 Pfizer Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
    • 2.1.5 Pfizer Recent Developments and Future Plans
  • 2.2 Astellas
    • 2.2.1 Astellas Details
    • 2.2.2 Astellas Major Business
    • 2.2.3 Astellas Castration-resistant Prostate Cancer Drugs Product and Solutions
    • 2.2.4 Astellas Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
    • 2.2.5 Astellas Recent Developments and Future Plans
  • 2.3 Janssen
    • 2.3.1 Janssen Details
    • 2.3.2 Janssen Major Business
    • 2.3.3 Janssen Castration-resistant Prostate Cancer Drugs Product and Solutions
    • 2.3.4 Janssen Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
    • 2.3.5 Janssen Recent Developments and Future Plans
  • 2.4 AstraZeneca
    • 2.4.1 AstraZeneca Details
    • 2.4.2 AstraZeneca Major Business
    • 2.4.3 AstraZeneca Castration-resistant Prostate Cancer Drugs Product and Solutions
    • 2.4.4 AstraZeneca Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
    • 2.4.5 AstraZeneca Recent Developments and Future Plans
  • 2.5 Bayer
    • 2.5.1 Bayer Details
    • 2.5.2 Bayer Major Business
    • 2.5.3 Bayer Castration-resistant Prostate Cancer Drugs Product and Solutions
    • 2.5.4 Bayer Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
    • 2.5.5 Bayer Recent Developments and Future Plans
  • 2.6 Hengrui
    • 2.6.1 Hengrui Details
    • 2.6.2 Hengrui Major Business
    • 2.6.3 Hengrui Castration-resistant Prostate Cancer Drugs Product and Solutions
    • 2.6.4 Hengrui Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
    • 2.6.5 Hengrui Recent Developments and Future Plans
  • 2.7 CTTQ
    • 2.7.1 CTTQ Details
    • 2.7.2 CTTQ Major Business
    • 2.7.3 CTTQ Castration-resistant Prostate Cancer Drugs Product and Solutions
    • 2.7.4 CTTQ Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
    • 2.7.5 CTTQ Recent Developments and Future Plans
  • 2.8 Sanofi
    • 2.8.1 Sanofi Details
    • 2.8.2 Sanofi Major Business
    • 2.8.3 Sanofi Castration-resistant Prostate Cancer Drugs Product and Solutions
    • 2.8.4 Sanofi Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
    • 2.8.5 Sanofi Recent Developments and Future Plans
  • 2.9 Hansoh
    • 2.9.1 Hansoh Details
    • 2.9.2 Hansoh Major Business
    • 2.9.3 Hansoh Castration-resistant Prostate Cancer Drugs Product and Solutions
    • 2.9.4 Hansoh Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
    • 2.9.5 Hansoh Recent Developments and Future Plans
  • 2.10 Clovis Oncology
    • 2.10.1 Clovis Oncology Details
    • 2.10.2 Clovis Oncology Major Business
    • 2.10.3 Clovis Oncology Castration-resistant Prostate Cancer Drugs Product and Solutions
    • 2.10.4 Clovis Oncology Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
    • 2.10.5 Clovis Oncology Recent Developments and Future Plans
  • 2.11 Zhendong Pharmaceutical
    • 2.11.1 Zhendong Pharmaceutical Details
    • 2.11.2 Zhendong Pharmaceutical Major Business
    • 2.11.3 Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Product and Solutions
    • 2.11.4 Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
    • 2.11.5 Zhendong Pharmaceutical Recent Developments and Future Plans
  • 2.12 Merck
    • 2.12.1 Merck Details
    • 2.12.2 Merck Major Business
    • 2.12.3 Merck Castration-resistant Prostate Cancer Drugs Product and Solutions
    • 2.12.4 Merck Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
    • 2.12.5 Merck Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Castration-resistant Prostate Cancer Drugs Revenue and Share by Players (2020-2025)
  • 3.2 Market Share Analysis (2024)
    • 3.2.1 Market Share of Castration-resistant Prostate Cancer Drugs by Company Revenue
    • 3.2.2 Top 3 Castration-resistant Prostate Cancer Drugs Players Market Share in 2024
    • 3.2.3 Top 6 Castration-resistant Prostate Cancer Drugs Players Market Share in 2024
  • 3.3 Castration-resistant Prostate Cancer Drugs Market: Overall Company Footprint Analysis
    • 3.3.1 Castration-resistant Prostate Cancer Drugs Market: Region Footprint
    • 3.3.2 Castration-resistant Prostate Cancer Drugs Market: Company Product Type Footprint
    • 3.3.3 Castration-resistant Prostate Cancer Drugs Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Castration-resistant Prostate Cancer Drugs Consumption Value and Market Share by Type (2020-2025)
  • 4.2 Global Castration-resistant Prostate Cancer Drugs Market Forecast by Type (2026-2031)

5 Market Size Segment by Application

  • 5.1 Global Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Application (2020-2025)
  • 5.2 Global Castration-resistant Prostate Cancer Drugs Market Forecast by Application (2026-2031)

6 North America

  • 6.1 North America Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2031)
  • 6.2 North America Castration-resistant Prostate Cancer Drugs Market Size by Application (2020-2031)
  • 6.3 North America Castration-resistant Prostate Cancer Drugs Market Size by Country
    • 6.3.1 North America Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2031)
    • 6.3.2 United States Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
    • 6.3.3 Canada Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
    • 6.3.4 Mexico Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)

7 Europe

  • 7.1 Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2031)
  • 7.2 Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2031)
  • 7.3 Europe Castration-resistant Prostate Cancer Drugs Market Size by Country
    • 7.3.1 Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2031)
    • 7.3.2 Germany Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
    • 7.3.3 France Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
    • 7.3.4 United Kingdom Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
    • 7.3.5 Russia Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
    • 7.3.6 Italy Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)

8 Asia-Pacific

  • 8.1 Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2031)
  • 8.2 Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2031)
  • 8.3 Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size by Region
    • 8.3.1 Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Region (2020-2031)
    • 8.3.2 China Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
    • 8.3.3 Japan Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
    • 8.3.4 South Korea Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
    • 8.3.5 India Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
    • 8.3.6 Southeast Asia Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
    • 8.3.7 Australia Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)

9 South America

  • 9.1 South America Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2031)
  • 9.2 South America Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2031)
  • 9.3 South America Castration-resistant Prostate Cancer Drugs Market Size by Country
    • 9.3.1 South America Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2031)
    • 9.3.2 Brazil Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
    • 9.3.3 Argentina Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)

10 Middle East & Africa

  • 10.1 Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2031)
  • 10.2 Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2031)
  • 10.3 Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size by Country
    • 10.3.1 Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2031)
    • 10.3.2 Turkey Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
    • 10.3.3 Saudi Arabia Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
    • 10.3.4 UAE Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)

11 Market Dynamics

  • 11.1 Castration-resistant Prostate Cancer Drugs Market Drivers
  • 11.2 Castration-resistant Prostate Cancer Drugs Market Restraints
  • 11.3 Castration-resistant Prostate Cancer Drugs Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Castration-resistant Prostate Cancer Drugs Industry Chain
  • 12.2 Castration-resistant Prostate Cancer Drugs Upstream Analysis
  • 12.3 Castration-resistant Prostate Cancer Drugs Midstream Analysis
  • 12.4 Castration-resistant Prostate Cancer Drugs Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Castration-resistant Prostate Cancer Drugs. Industry analysis & Market Report on Castration-resistant Prostate Cancer Drugs is a syndicated market report, published as Global Castration-resistant Prostate Cancer Drugs Market 2025 by Company, Regions, Type and Application, Forecast to 2031. It is complete Research Study and Industry Analysis of Castration-resistant Prostate Cancer Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo